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Vital exhaustion and cardiovascular prognosis in
myocardial infarction and heart failure: predictive
power of different trajectories
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2 Department of Health Promotion and Development, Faculty of Psychology, University of Bergen, Bergen, Norway
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Background. We examined the different trajectories of vital exhaustion (VE) over a 12-month period and their impact
on prognosis in a sample of myocardial infarction (MI) and chronic heart failure (CHF) patients.
Method. Consecutive MI (n=407) and CHF patients (n=297) were assessed at baseline, and at 3- and 12-month
follow-up for symptoms of VE. Latent growth mixture modelling was used to examine the course of VE over time.
The combined clinical endpoint was defined as cardiac hospital readmission or death.
Results. Four distinct trajectories for VE were found : low VE, decreasing VE, increasing VE, and severe VE. Sex,
marital status, left ventricular ejection fraction, psychotropic medication, sample group (CHF v. MI) and depressive
symptoms were associated with VE, varying according to classes. The mean follow-up period was 25.3 months in
which 34.7% of the patients experienced an event. Multivariate Cox regression showed that, compared with patients
in the low VE class, patients in the increasing VE class [hazard ratio (HR)=1.16, 95% confidence interval (CI)
1.58–3.61, p=0.01], and the severe VE class (HR=1.69, 95% CI 1.31–2.64, p=0.02) had an increased risk for adverse
cardiovascular events (i.e. cardiovascular hospital readmission or cardiovascular death). Decreasing VE was not
related to adverse cardiovascular events (HR=0.97, 95% CI 0.66–1.69, p=0.81).
Conclusions. VE trajectories varied across cardiac patients, and had a differential effect on cardiovascular outcome.
Increasing VE and severe VE classes were predictors of poor cardiovascular prognosis. These results suggest that
identification of cardiac patients with an increased risk of adverse health outcomes should be based on multiple
assessments of VE.
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Introduction
Vital exhaustion (VE) is a frequently observed
phenomenon in patients with coronary artery disease
and chronic heart failure (CHF) (Appels et al. 1995 ;
Pedersen & Middel, 2001 ; Smith et al. 2009). The most
commonly used definition of VE is that of unusual
tiredness, increased irritability, and feelings of de-
moralization (Appels et al. 1987). VE has been associ-
ated with a 2- to 3-fold increased risk of mortality and
morbidity in patients with coronary artery disease
(Kop et al. 1994 ; Appels et al. 1995 ; Smith et al. 2009),
and several potential biological pathways have been
suggested which may explain this association. VE has
been shown to relate to increased lipid metabolism
(van Doornen & van Blokland, 1989), hypocortiso-
laemia (Keltikangas-Järvinen et al. 1996 ; Nicolson &
van Diest, 2000), reduced fibrinolytic capacity (Kop
et al. 1998 ; van Diest et al. 2002), parasympathetic
withdrawal (Watanabe et al. 2002), reduced heart rate
recovery after exercise (von Kanel et al. 2009) and in-
creased levels of cytokines, e.g. interleukin-6 (van der
Ven et al. 2003 ; Janszky et al. 2005).
The 21-item Maastricht Questionnaire is often used
to assess VE (Appels et al. 1987). Previous studies have
shown that VE as measured by the Maastricht Ques-
tionnaire is not similar to symptoms of fatigue, but
additionally comprises factors such as depressive
symptoms, sleep problems and lack of concentration
(Kudielka et al. 2004; McGowan et al. 2004 ; Pedersen
et al. 2007 ; Smith et al. 2009). A few other studies
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examined the overlap between VE and depressive
symptoms. In a large-scale study (Kopp et al. 1998), VE
and depressive symptoms were differently related to
relevant external criteria, suggesting that the con-
structs are distinct from each other. Furthermore,
VE and depression shared less than 40% of the vari-
ance. The latter result was confirmed by other studies
(Kudielka et al. 2004 ; McGowan et al. 2004). VE has
been shown to be prevalent in both patients with
myocardial infarction (MI) and CHF patients (Appels
et al. 2000 ; Smith et al. 2009), but it is not clear whether
levels of VE differ across these patient groups. Given
disease stage, VE might also be differently related to
cardiovascular prognosis.
Although previous studies have stressed the im-
portance of VE in cardiac disease (Appels & Mulder,
1988 ; Appels, 1990 ; Appels & Otten, 1992 ; Smith et al.
2009), there is a paucity of research on the evolution
and/or persistence of VE. Patients may have varying
courses of VE and, hence, potentially differential risks
of adverse health outcomes. Knowledge of VE trajec-
tories, their clinical and psychological characteristics,
and their prognostic impact might allow for the identi-
fication of high-risk cardiac patients who may need
additional clinical care above and beyond the standard
medical management of the disease.
Since the course of VE has not been studied in
cardiac patients, the current study’s objective was
to examine: (1) the course and characteristics of VE
during a 12-month period and (2) their impact on




To cover both acute and chronic cardiac disease,
we combined two different samples. One sample of
patients who recently had a MI was included to reflect
acute cardiac disease, whereas a second sample of
patients suffering from CHF was included to reflect
chronic cardiac disease. This resulted in a total sample
of 704 patients. The MI patients comprised 407
patients that participated in the Depression after
Myocardial Infarction (DepreMI) study (Kaptein et al.
2006), which is a naturalistic follow-up study of the
impact of depressive symptoms on cardiac prognosis
in MI patients in four hospitals in the North of The
Netherlands. Patients admitted for an MI between
September 1997 and September 2000 were included
and followed until April 2002. Inclusion criteria were :
(a) chest pain for at least 20 min, (b) creatinine phos-
phokinase levels 100% above normal or creatinine
phosphokinase-MB levels above 10%, and (c) presence
of new pathological Q waves on the electrocardiogram
in at least two leads. Exclusion criteria were life
expectancy of less than 1 year (because of non-cardiac
condition), too poor physical condition according to
hospital staff, cognitive dysfunction, inability to speak
or read Dutch, occurrence of an MI in patients ad-
mitted for another reason, and follow-up visits sched-
uled in a non-participating hospital. Patients received
usual aftercare for their MI and depressive symp-
toms. Of the 528 patients that were initially included,
60 patients were lost during follow-up (i.e. refusal,
death), and 61 patients had missing questionnaire
data on two or more measurement points, leaving
407 patients for the MI database used in the present
study.
The CHF patients comprised 297 consecutive
patients with systolic heart failure and a left ventricu-
lar ejection fraction (LVEF) f40%, visiting the heart
failure out-patient clinic of the TweeSteden hospital,
Tilburg, The Netherlands. Patients with diastolic
heart failure, age o80 years, MI in the month prior to
inclusion, other life-threatening diseases, and no or
insufficient understanding of the spoken and written
Dutch language were excluded beforehand. Of the
378 patients that were initially included, 44 patients
died during the first year of the study, and 37 patients
had missing questionnaire data on two or more
measurement occasions, leaving 297 patients for the
present study.
Both MI and CHF patients completed a question-
naire at baseline, 3-month follow-up and 12-month
follow-up. The study protocol was approved by the
institutional review boards of the participating hos-
pitals, and was conducted conforming to the Helsinki
Declaration. Every patient provided written informed
consent.
VE
VE was assessed by the 21-item Maastricht Ques-
tionnaire (Appels et al. 1987). Each item was originally
rated according to a three-point scale (yes=0 ; ?=1;
no=2), and a total score was calculated by summing
the answers. The question mark was included for
patients that could not decide between yes and no.
The internal construct reliability of the total scale is
good, with a Cronbach’s a of 0.89 (Kop et al. 1994).
Frequency analysis on every single item revealed that
the question mark category was rarely used (<10%).
Therefore, we decided to divide the total scores by a
factor of 2 and to round up to integers at a 0.5 level.
Hereby, we considered these scores as count variables
of the number of VE symptoms. From a psychometric
perspective, this is more appropriate than using the
scores as a continuous variable. Choosing the right
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variable type and subsequent underlying distribution
is of particular importance for the latent class analysis
(LCA) that is introduced in the statistical analyses
paragraph.
Symptoms of depression
Symptoms of depression were measured by means of
the Beck Depression Inventory (BDI) (Beck & Steer,
1993). Each item is rated on a 0–3 scale. A total score is
obtained by summing together all the items. The BDI
is a reliable and well-validated measure of depressive
symptomatology (Beck et al. 1988), and is a widely
used self-report measure of depression. This subscale
was dichotomized using the standardized BDI cut-off
score of o10 versus BDI scores <10. The correlation
between VE at baseline and depressive symptoms at
baseline was 0.52, and therefore share 27% of the
variance.
Demographic and clinical variables
Demographic variables included sex, age (<60 years
v. o60 years) and marital status (partner v. no
partner). Clinical variables comprised smoking status,
LVEF (<40% v. o40%), previous MI, diabetes melli-
tus and cardiac medication. Information on clinical
variables was obtained from the medical records and
from the treating cardiologist or heart failure nurse.
Cardiovascular prognosis
The combined clinical endpoint was defined as cardio-
vascular hospital readmission or cardiovascular death.
Information on potential endpoints was collected from
hospital records and the patients’ primary care phys-
icians. Mean follow-up duration was 25.4 months
[standard deviation (S.D.)=13.3 months].
Statistical analyses
LCA was employed to examine trajectories of VE
symptoms in cardiac patients over a 12-month period
(Vermunt & Magidson, 2000). A latent growth Poisson
mixture model was fitted to the longitudinal VE data
to identify classes of individuals following similar
patterns of behaviour over time. The model assumes
unobserved latent variables to explain the associations
among observed scores, and can be seen as a categ-
orical equivalent of factor analysis. One of the prob-
lems with fitting these types of latent class models is
that the categorization into classes is dominated by the
overall symptom levels, making it less likely that the
model picks up symptom changes. A way to overcome
this problem is the inclusion of a random intercept
(Magidson & Vermunt, 2006).
To determine the optimal number of trajectories,
Akaike’s Information Criterion 3 (AIC3) was used,
with a lower AIC3 indicating a better fit. However,
a difference of less than 3 will favour the least com-
plex model. Recent studies have shown that AIC3
is a better criterion than the Bayesian ICnformation
criterion and Akaike’s Information Criterion in de-
termining the number of latent classes in latent class
models (Andrews & Currim, 2003; Dias, 2004).
For comparison between classes we used the x2
test for discrete variables. Adjusted standardized
residuals (ASRs) were used to identify groups re-
sponsible for significant differences. A residual >2.0
was taken to indicate a significantly higher frequency,
and a residual <x2.0 was considered to indicate a
significantly lower frequency than expected if the in-
dependence hypothesis was true (Everitt, 1977).
Multivariate Cox proportional hazards regression
was used to assess whether VE trajectories predicted
the combined endpoint of cardiovascular readmission
or death. In the regression model, we included age,
sex, marital status, smoking status, diabetes mellitus,
previous MI, disease severity (LVEF), beta blockers,
calcium antagonists, aspirin, psychotropics and de-
pressive symptoms because of their relationship with
cardiovascular prognosis (Gradman & Deedwania,
1994 ; Frasure-Smith et al. 1995 ; Wilson et al. 1998 ;
Ormiston & Salpeter, 2003 ; Grossman & Messerli,
2004 ; Rumsfeld et al. 2005; Eaker et al. 2007; Kovacs &
Arora, 2008). The LCA was performed with the pro-
gram Latent Gold 4.5 (Vermunt & Magidson, 2000 ;
Statistical Innovations, USA). All other data were
analysed using SPSS 15.0.1 for Windows (SPSS Inc.,
USA). A similar approach has previously been used
in MI patients (Martens et al. 2008), percutaneous
coronary intervention (PCI) patients (Pedersen et al.
2008) and peripheral arterial disease (PAD) patients
(Smolderen et al. 2008).
Results
Trajectories of VE
Fig. 1 displays the four distinct developmental trajec-
tories for VE. AIC3 improved from one class of VE
(AIC3=11526) to four classes of VE (AIC3=11315),
with both the three-class model (AIC3=11323) and the
five-class model (AIC3=11322) showing a signifi-
cantly worse fit compared with the four-class model
(AIC3=11315). The four-class model was therefore
adopted for further analysis.
The first class (16.8% of the sample) was classified
as the low VE group (intercept=0.57, p<0.001;
slope=x0.06, p<0.001), and had low levels of VE
on all time points. The second class (29.1%) was
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characterized by a decrease in VE symptoms over time
(intercept=1.81, p<0.001 ; slope=x0.06, p<0.001).
The third class (8.1%) was described as increasing
VE (intercept=1.30, p<0.001; slope=0.03, p=0.09).
Finally, the fourth class (46.0%) was classified as
severe VE (intercept=2.38, p<0.001; slope=x0.0023,
p=0.34) with high levels of VE on all time points.
Characteristics of VE trajectories
There were a number of differences in demographic,
clinical and psychological characteristics at baseline
as a function of VE class (Table 1). Departure from
independence was most pronounced in the extreme
VE groups (Table 1 ; denoted by footnote a), as these
showed the most significant relationships with the
baseline characteristics. Patients in the low VE group
were more likely to be male (ASR=3.0) and to have
a partner (ASR=x2.5). In addition, they were less
likely to be on psychotropics (ASR=x2.8) and to be
depressed (ASR=x6.4). Patients in the decreasing VE
group were less likely to be depressed (ASR=x7.0).
Other deviations were not observed in this class.
Patients in the increasing VE group were more likely
to be male (ASR=3.1) and to be an MI patient (Fig. 2).
Furthermore, these patients were less likely to be
depressed (ASR=x3.9). Finally, patients in the sev-
ere VE group were more likely to be female (ASR=
x4.8), alone (ASR=3.0), on psychotropic medication
(ASR=5.2), depressed (ASR=13.3) and to have de-
creased LVEF (ASR=2.5). As displayed in Fig. 2, CHF
patients were more likely to be in the severe VE group
as compared with MI patients (ASR=3.1), indepen-
dent of LVEF.
Trajectories of VE and cardiovascular prognosis
The mean follow-up period was 25.4 months (S.D.=
13.3 months). During this period, 244 patients (34.7%)
experienced an adverse cardiovascular event. Lower
LVEF was associated with an increased risk for ad-
verse cardiovascular events (Table 2). Previous MI
























Fig. 1. Observed trajectories of vital exhaustion. –&–,
Severe vital exhaustion (46.0%) ; –m–, increasing vital
exhaustion (8.1%) ; –n–, decreasing vital exhaustion (29.1%) ;
–%–, low vital exhaustion (16.8%). Values are means,
with standard deviations represented by vertical bars.














Male sex 76.6 (539) 87.3 (103)a 79.0 (162) 93.0 (53)a 68.2 (221)a <0.001
Age o60 years 62.9 (443) 55.1 (65) 67.3 (138) 61.4 (35) 63.3 (205) 0.18
Having no partner 19.2 (135) 11.0 (13)a 18.0 (37) 12.3 (7) 24.1 (78)a 0.007
Smoking 38.2 (269) 40.7 (52) 32.7 (66) 50.9 (29) 38.9 (126) 0.06
Previous MI 29.8 (210) 21.2 (25) 31.2 (64) 22.8 (13) 33.3 (108) 0.05
Diabetes 15.2 (107) 11.9 (14) 16.1 (33) 5.3 (3) 17.6 (57) 0.07
Heart failureb 42.2 (297) 37.3 (44) 39.5 (81) 26.3 (15)a 48.5 (157)a 0.005
LVEF <40% 56.0 (394) 50.0 (59) 54.1 (111) 45.6 (26) 61.1 (198)a 0.05
Beta blockers 72.5 (510) 78.8 (93) 69.8 (143) 75.4 (43) 71.5 (231) 0.32
Calcium antagonists 17.5 (123) 19.5 (23) 16.6 (34) 19.3 (11) 17.0 (55) 0.89
Aspirin 67.3 (474) 66.1 (78) 69.3 (142) 75.4 (43) 65.1 (211) 0.42
Psychotropics 8.1 (57) 1.7 (2)a 4.4 (9) 1.8 (1) 6.4 (45)a <0.001
Depressive symptoms 27.6 (194) 3.4 (4)a 9.3 (19)a 5.3 (3)a 51.9 (168)a <0.001
MI, Myocardial infarction ; LVEF, left ventricular ejection fraction.
Values are given as percentage (number of subjects).
a Absolute adjusted standardized residual >2.0.
b Chronic heart failure group as compared with the MI group.
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Univariate Cox regression analysis revealed that
the event rate in the increasing VE class (38.6% v.
22.3%, p=0.03) and the severe VE class (42.9%
v. 22.3%, p=0.001) was significantly higher as com-
pared with the low VE class. The decreasing VE class
(27.3% v. 22.3%, p=0.42) did not have a significantly
different event rate as compared with the low VE class.
In multivariate analysis, increasing VE and severe
VE remained significant predictors of adverse cardio-
vascular events (Table 2). Compared with the low VE
group, patients in the increasing VE class [hazard ratio
(HR)=1.16, 95% confidence interval (CI) 1.58–3.61,
p=0.01] and in the severe VE class (HR=1.69, 95% CI
1.31–2.64, p=0.02) had an increased risk for cardio-
vascular events. Patients in the decreasing VE class
had a similar risk for cardiovascular events (HR=0.97,
95% CI 0.66–1.69, p=0.81) as compared with the low
VE class. Adding sample group (MI v. CHF) as a pre-
dictor did not significantly alter the results presented
in Table 2.
Trajectories versus raw scores at one time point
as outcome predictors
To assess whether the trajectory model presented in
Table 2 yields a better prediction of adverse outcomes
as compared with using raw VE scores at single time
points, the multivariable analysis was repeated three
times after replacing the group bases trajectory vari-
ables with raw VE scores at, respectively, baseline,
2-month follow-up and 12-month follow-up. Raw VE
scores were all independent predictors of adverse
outcome in CVD patients (VE model at baseline :
HR=1.01, 95% CI 1.01–1.07, p=0.006; VE model at
2-month follow-up: HR=1.03, 95% CI 1.001–1.06,
p=0.05 ; VE model at 12-month follow-up: HR=1.05,
95% CI 1.02–1.08, p<0.001). Model comparison by
means of a log-likelihood ratio test revealed that the
trajectory model outperformed the baseline (x2=6.1,
df=2, p=0.05) and 2-month follow-up model (x2=9.3,
df=2, p=0.01), but had similar predictive power
as the 12-month follow-up model (x2=2.5, df=2,
p=0.29).
Discussion
To our knowledge, this is the first study to examine the
course of VE in a combined sample of MI and CHF
patients. We found four distinct trajectories for VE:
(i) low levels of VE at all time points ; (ii) decreasing
levels of VE over time; (iii) increasing levels of VE over
time; (iv) high levels of VE at all time points. Sex,
marital status, LVEF, psychotropic medication, sample
group (CHF v. MI) and depressive symptoms were
associated with VE, varying according to classes.
Multivariate Cox regression showed that patients in
the increasing VE class and in the severe VE class had
an increased risk for adverse cardiovascular events as
compared with patients in the low VE class, indepen-
dent of covariates. Patients in the decreasing VE class
had a similar risk for cardiovascular events as com-
pared with the reference category. Finally, the group-
based trajectory prediction model outperformed
models with raw VE scores at baseline, and 2-month
follow-up, but had similar predictive power as raw


















Fig. 2. Percentage of patients per vital exhaustion (VE) class
stratified by sample group and left ventricular ejection
fraction (LVEF). (%), Myocardial infarction (MI)+LVEF
o40%; ( ), MI+LVEF <40%; (&), chronic heart failure
(CHF). * Percentage was significantly different from that for
CHF patients (p<0.05).
Table 2. Trajectories of vital exhaustion and cardiac prognosis
(multivariate)
Variable HR (95% CI) p
Male sex 0.97 (0.71–1.32) 0.82
Age o60 years 1.16 (0.86–1.58) 0.33
Having no partner 0.95 (0.69–1.31) 0.76
Smoking 1.08 (0.81–1.43) 0.61
Previous MI 1.32 (0.99–1.75) 0.06
Diabetes 1.28 (0.93–1.77) 0.14
LVEF <40% 1.94 (1.36–2.75) <0.001*
Beta blockers 0.80 (0.60–1.06) 0.13
Calcium antagonists 0.81 (0.56–1.18) 0.27
Aspirin 0.84 (0.63–1.11) 0.21
Psychotropic medication 1.26 (0.84–1.91) 0.27
Depressive symptoms 1.13 (0.82–1.54) 0.45
Decreasing vital exhaustion 1.06 (0.66–1.69) 0.81
Increasing vital exhaustion 2.04 (1.15–3.61) 0.01*
Severe vital exhaustion 1.69 (1.08–2.64) 0.02*
HR, Hazard ratio ; CI, confidence interval ; MI, myocardial
infarction ; LVEF, left ventricular ejection fraction.
* p<0.05.
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The results of the present study advocate the use of
latent growth mixture modelling to study the course
of symptom levels over time, which has also been
argued in other studies (Kaptein et al. 2006 ; Martens
et al. 2008 ; Pedersen et al. 2008 ; Smolderen et al. 2008).
Similar to our study, these investigations have also
found support for multiple rather than one trajectory,
although they studied depression (Kaptein et al. 2006 ;
Martens et al. 2008 ; Smolderen et al. 2008) and anxiety
(Pedersen et al. 2008). Our approach, however, was
somewhat different from the previous studies because
(1) we allowed the error terms to vary within classes
which was not the case in the study of Kaptein et al.
(2006), and (2) we included a random intercept to re-
move the overall response level effects (Magidson &
Vermunt, 2006). In our opinion, both adjustments im-
proved the model specification considerably, as was
demonstrated by higher AIC3 values (not reported)
in VE models with fixed error terms and without a
random intercept.
The most important finding we feel is that two
trajectories of VE were associated with an increased
risk of cardiovascular events, representing chronic
severely exhausted patients and patients in which
levels of VE increased during the follow-up year. Of
interest, MI patients were relatively more present
in the increasing VE class as compared with CHF
patients. Our findings thus suggest that a significant
number of patients do not fully recover after an MI but
deteriorate over time, which in the current study is
expressed as an increase in the number of VE symp-
toms and subsequently an increased cardiac risk.
Patients in this class might reflect a group of patients
that do not respond to standard treatment procedures.
These findings appear to be consistent with previous
observations by Carney et al. (2004), de Jonge et al.
(2007) and Kaptein et al. (2006) who found that per-
sistence of depressive symptoms (despite treatment)
was associated with an increased cardiac risk. Of note,
in those studies depression was assessed with the BDI,
in which somatic symptoms of depression (such as
fatigue and sleeping difficulties) are relatively over-
represented. In contrast, CHF patients were relatively
more present in the severe VE class. CHF patients on
average have a longer and more severe cardiac history
and did not experience a recent acute coronary syn-
drome. CHF patients may therefore display a more
stable pattern of VE over time. As a consequence,
the most vulnerable class of CHF patients is charac-
terized by a chronic, severe level of VE. Thus, the most
vulnerable MI and CHF patients may differ in their
patterns of VE.
Notably, the two VE trajectories predicted cardiac
outcome independent of depression symptoms at
baseline. This either could mean that depression and
VE are related, but not similar, constructs that relate
to cardiac outcome because of different reasons, but
also could indicate that the VE trajectories give a more
precise indication of the status of the patient, as a time
factor is included, making it a better predictor of
cardiac outcome. The first explanation is supported by
our previous findings that the VE symptom clusters of
fatigue and cognitive-affective depressive symptoms
were responsible for having a poorer health status
(Smith et al. 2009).
From a clinical point of view, knowledge about
factors characterizing trajectories that display changes
over time is important as they point to targets for
intervention. Importantly, the findings of the present
study indicate that VE trajectories are differently re-
lated to an increase of adverse cardiovascular events.
In a previous study, we have shown that symptom
profiles of VE in CHF patients, measured at a single
time point, were associated with rehospitalization
(Smith et al. 2009). It would be interesting to study
these symptom profiles using a latent growth mixture
modelling approach, and examine the effect of symp-
tom profile trajectories on cardiovascular prognosis.
Furthermore, in the multivariate Cox model, we con-
trolled for depressive symptoms measured at baseline,
and demonstrated that trajectories of VE indepen-
dently predicted our outcome measure. The potential
effects of depressive symptoms at later time points
were ignored. It would be worthwhile to investigate
the distinctiveness of VE and depression using a joint
trajectory modelling approach (Jones & Nagin, 2005),
providing full control of each other’s effects on out-
come measures. Generally, large-scale studies should
give a more in-depth insight into the differential effect
of the VE trajectories on cardiovascular prognosis.
The results of the present study might help to
guide future interventions. It is important to note that
results from the EXhaustion Intervention Trial (EXIT)
showed that VE was influenced by the intervention
depending upon a prior history of coronary artery
disease (CAD) (Appels et al. 2006). Since this study
included patients with CAD (previous MI) and CHF,
it should be taken into account that interventions
might not equally benefit the course of these two
cardiac diseases.
This study has a number of limitations. First, only
the patients who lived to the end of the assessment
process were included in the study. This may have
introduced potential selection bias, and may under-
or overestimate the effects of VE found in this study.
Second, the cardiologist or heart failure nurses asked
patients to participate in the study, and this inter-
action pattern might have influenced patient selection.
Third, the examined predictors of the VE trajectories
were only assessed once. Given that, for example,
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depressive symptoms were identified as an indepen-
dent predictor of persistent VE, it is possible that
these levels may be attributed to persistent depressive
symptoms, rather than baseline levels. Fourth, we
were not able to control for some potentially important
variables in the multivariable analyses as a result of
combining two databases that did not fully match
[e.g. blood pressure, body mass index, physical exer-
cise, alcohol consumption, severity of MI, angiotensin-
converting enzyme (ACE) inhibitors]. Nevertheless,
the strengths of the current study were the repeated
assessment of VE over time, the prospective design
examining the course of VE over time using a state-
of-the-art modelling approach, and the use of a semi-
objective medical outcome. Finally, we used a reliable
and valid measure of VE.
In summary, we found four distinct trajectories for
VE. Several predictors, varying according to classes,
could be identified, with sex, marital status, LVEF,
psychotropic medication, sample group (CHF v. MI)
and depressive symptoms being the most prominent
ones. Increasing VE class and the severe VE class had
an increased risk for adverse cardiovascular events
as compared with the low VE class. Patients in the
decreasing VE class did not have an increased risk
for adverse events as compared with the reference
category.
Future studies are warranted to confirm these find-
ings, given that this was the first study to examine
the course of VE in cardiac patients. The results of the
present study may help identify distinct groups of
patients with potentially differential risks of adverse
health outcomes, guide future interventions, and
therefore be valuable for both research and clinical
practice.
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